Staph. haemolyticus


>Staphylococcus Coagulase-negative species:
     1] Staph epidermidis
     2] Staph. haemolyticus led
     3] Staph lugdunensis
     4] Staph saprophyticus
     5] Staph hominis
     6] Staph capitis

Staphylococcus haemolyticus:

  • Non-motile, non-sporulating, facultatively anaerobic, and Gram-stain positive. 
  • Member of the coagulase-negative staphylococci (CoNS).
  • It is part of the skin flora of humans, and its largest populations are usually found at the axillae, perineum, and inguinal areas.
  •  It is a well-known opportunistic pathogen, and is the second most frequently isolated CoNS (S. epidermidis is the first).
  • Infections can be localized or systemic, and are often associated with the insertion of medical devices.
  • The highly antibiotic resistant phenotype and ability to form biofilms make S. haemolyticus a difficult pathogen to treat.


top of page


Important considerations:  The choice of an agent should be based on local antimicrobial sensitivities, site of infection, cost, and comorbid conditions.   Generally, the most common agents/regimens are listed first.  Listed dosages may need to be adjusted for renal dysfunction.

S. haemolyticus has the highest level of antibiotic resistance among the (CoNS) coagulase-negative staphylococci

  1. Vancomycin – (patient-specific regimen – trough goal 15-20 mcg/ml)
  2. Linezolid 600 mg orally or IV q12h 
  3. Daptomycin 4 – 6 mg/kg IV once daily.   NOT FOR PNEUMONIA


The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user’s use of or reliance upon this material.PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read the disclaimer